#United States #Phoenix #BioLab Holdings #Wound Healing #Membrane Wrap

BioLab Holdings Announces New Trial for Membrane Wrap™

BioLab Holdings, Inc., a Phoenix-based company specializing in wound healing and wound care solutions, has exciting news to share. They have officially obtained Institutional Review Board (IRB) approval for a randomized control trial to assess the effectiveness of their cutting-edge product, Membrane Wrap™, in treating venous leg ulcers. This initiative marks a significant step for the company as they embark on essential clinical research, aimed at enhancing the quality of care for patients suffering from chronic wounds.

The Clinical Trial Details

The trial, titled "A Multi-Center, Prospective, Randomized Trial Evaluating the Efficacy of Membrane Wrap, a Human Amniotic Membrane, on Venous Leg Ulcers in an Elderly Population," is being conducted in collaboration with the Multi-Clinical Research Associates (MCRA) located in Washington D.C. Dr. Marshall Medley, the Chief Medical Officer at BioLab, expressed enthusiasm about this trial, noting its importance in validating the efficacy of Membrane Wrap™. He shared, "We are very excited to be involved in this trial to ensure our Membrane Wrap's efficacy. This is the first of several randomized control trials we will be involved in, and we look forward to getting our products to even more patients in need of wound care."

The trial will take place across 18 carefully selected clinical sites, with enrollment set to start in the upcoming weeks as agreements with these sites are finalized. This research initiative is crucial as it seeks to establish the Membrane Wrap™ as a viable treatment option for venous leg ulcers, a common challenge in the elderly due to various underlying health issues.

Unique Approach to Wound Care

What sets BioLab apart from other manufacturers in the wound care sector is their holistic approach to product support. Before introducing their skin substitutes to new providers, BioLab conducts thorough training sessions covering product protocols, application techniques, insurance verifications, and billing practices. Furthermore, they offer continual assistance post-application, helping providers with guidance on rejected claims and ensuring that patients receive charitable assistance when needed.

This commitment to comprehensive support exemplifies BioLab's dedication not only to innovation in their product offerings but also to the overall success of their partners before and after the use of their products. By ensuring that healthcare providers are well-equipped to use their products effectively, BioLab aims to improve patient outcomes significantly.

Looking Ahead

As BioLab Holdings moves forward with this promising trial, the company is committed to providing ongoing updates regarding its progress and future findings. Their mission is clear: to manufacture high-quality, reliable products that enhance patient care through continuous learning, innovation, and collaboration with healthcare professionals.

For those interested in the evolution of wound care solutions, staying tuned to BioLab’s developments will be essential. To learn more about BioLab Holdings, its innovative products like the Membrane Wrap™, or to access their extensive suite of services, visit biolabholdings.net.

In conclusion, BioLab Holdings, Inc. is set to impact the wound care sector significantly, improving the lives of many patients and setting new standards for treatment efficacy and provider support.